- Amgen and the FDA want two different outcomes for Tavneos. What will patients do?Amgen has asked the FDA to review evidence that its drug Tavneos (avacopan), which treats a rare form of vasculitis, is worth keeping on the market, as the future of the drug remains in flux. ...Endpoints · 1mo ago↗ source
- Eli Lilly invests in startup Abridge for clinical trial recruitmentEli Lilly has invested in Abridge as the health tech startup expands into clinical trial recruitment and broadens its reach into the life sciences. The investment, made through Lilly’s venture ar…Endpoints · 1mo ago↗ source
- Enliven prices $400M offering; Jazz drug Zepzelca fails confirmatory studyPlus news about Caribou, Adial, and the Beneluxa Initiative. 💵 Enliven Therapeutics’ data and raise: The Burlingame, CA-based biotech priced a $400 million offering {$ELVN} Thursday night after…